An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension

Trial Profile

An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension: IMPRES Extension

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Imatinib (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Acronyms IMPRES Extn
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 25 May 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
    • 11 May 2014 New trial record
    • 03 Feb 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top